The shifting of the center of a slice stack from the center of the magnetic field for positioning of the measured area.

Omniscan® is a nonionic chelate complex with low osmolality used as a paramagnetic MRI contrast agent. The efficacy of Omniscan® is similar to that of Gd-DTPA. Omniscan® is given intravenously to enhance images of intracranial and spinal lesions where there is abnormal vascularity or an abnormal blood brain barrier. The complex does not cross an intact blood brain barrier so Omniscan® only accumulates in lesions such as neoplasm's and abscesses.

WARNING: NEPHROGENIC SYSTEMIC FIBROSIS Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis (NSF) in patients with acute or chronic severe renal insufficiency (glomerular filtration rate less than 30 mL/min/1.73m²), or acute renal insufficiency of any severity due to the hepato-renal syndrome or in the perioperative liver transplantation period.

See also Gadodiamide, and Classifications, Characteristics, etc.

A state occurring when the Larmor frequency of a spin isochromat is the same as that of the exciting RF field.

See also Magnetization Transfer Contrast.

Oncomembrane, Inc. is a distribution diversity of Otsuka America. Otsuka America representative confirmed FerriSeltz, with an internal capital S.
Source: FDA drug approvals - 10/14/97

MRI Contrast Agents:

Please note that the product name is found as both Ferriseltz and FerriSeltz.

Founded in June 1997, ONI was a privately held company headquartered in Wilmington, Massachusetts. ONI was focused on addressing the new healthcare economics by delivering the next generation of MRI machines: high field, low cost dedicated purpose systems. The company's first offering was the OrthOne™. Further developments lead to the MSK Extreme™, a 1.0 Tesla dedicated purpose MR system with v-SPEC™ Technology and DICOM Conformance for extremity applications.
In October 2009 GE Healthcare bought ONI Medical Systems for US$ 17 Billion.

MRI Scanners:

1.0T: